Table 3.

Selected ongoing phase III clinical trials involving anti-angiogenic inhibitors combined with cancer immunotherapy.

Tumor Type	Combination Drugs	Study Status	NCT ID
Stage IV NSCLC	Atezolizumab+Carboplatin+paclitaxel+Bevacizumab	Active, not recruiting	NCT02366143
Advanced RCC	Bevacizumab+Atezolizumab	Active, not recruiting	NCT02420821
Advanced RCC	Avelumab+Axitinib	Active, not recruiting	NCT02684006
Advanced RCC	Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab	Recruiting	NCT02811861
Recurrent OC, FTC, or PPC	Pegylated Liposomal Doxorubicin+Atezolizumab+Bevacizumab	Recruiting	NCT02839707
RCC	Pembrolizumab+Axitinib	Active, not recruiting	NCT02853331
Late relapse OC	Atezolizumab+Chemotherapy+Bevacizumab	Recruiting	NCT02891824
OC,FTC,or PPC	Atezolizumab+Carboplatin+paclitaxel+Bevacizumab	Recruiting	NCT03038100
Early relapse OC	Atezolizumab+Bevacizumab+Chemotherapy	Recruiting	NCT03353831
Locally Advanced or Metasatatic HCC	Atezolizumab+Bevacizumab	Recruiting	NCT03434379